ALDX
Price:
$5.18
Market Cap:
$307.80M
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for ...[Read more]
Industry
Biotechnology
IPO Date
2014-05-02
Stock Exchange
NASDAQ
Ticker
ALDX
According to Aldeyra Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -33.33%. This represents a change of 282.11% compared to the average of -8.72% of the last 4 quarters.
The mean historical ROE of Aldeyra Therapeutics, Inc. over the last ten years is -60.92%. The current -33.33% ROE has changed -45.30% with respect to the historical average. Over the past ten years (40 quarters), ALDX's ROE was at its highest in in the December 2023 quarter at -3.97%. The ROE was at its lowest in in the December 2014 quarter at -38.90%.
Average
-60.92%
Median
-52.51%
Minimum
-126.51%
Maximum
-28.80%
Discovering the peaks and valleys of Aldeyra Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 181.74%
Maximum Annual ROE = -28.80%
Minimum Annual Increase = -110.21%
Minimum Annual ROE = -126.51%
Year | ROE | Change |
---|---|---|
2023 | -31.34% | -22.89% |
2022 | -40.64% | 41.10% |
2021 | -28.80% | -54.36% |
2020 | -63.11% | -50.12% |
2019 | -126.51% | 181.74% |
2018 | -44.90% | -20.41% |
2017 | -56.41% | -34.68% |
2016 | -86.37% | 77.73% |
2015 | -48.60% | -41.13% |
2014 | -82.55% | -110.21% |
The current ROE of Aldeyra Therapeutics, Inc. (ALDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-33.59%
5-year avg
-58.08%
10-year avg
-60.92%
Aldeyra Therapeutics, Inc.’s ROE is greater than Tarsus Pharmaceuticals, Inc. (-63.99%), greater than LianBio (-31.46%), greater than Travere Therapeutics, Inc. (-541.59%), greater than Eton Pharmaceuticals, Inc. (-43.62%), greater than Viridian Therapeutics, Inc. (-49.65%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Structure Therapeutics Inc. (-20.15%), greater than Blueprint Medicines Corporation (-47.66%), greater than 89bio, Inc. (-35.42%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than HOOKIPA Pharma Inc. (-51.77%), less than Phathom Pharmaceuticals, Inc. (251.33%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Cullinan Oncology, Inc. (-28.37%), greater than BioLineRx Ltd. (-225.62%), greater than Ardelyx, Inc. (-46.60%), less than Lexicon Pharmaceuticals, Inc. (73.27%), less than Seres Therapeutics, Inc. (313.56%), less than ImmunityBio, Inc. (100.06%),
Company | ROE | Market cap |
---|---|---|
-63.99% | $1.76B | |
-31.46% | $34.47M | |
-541.59% | $1.41B | |
-43.62% | $215.73M | |
-49.65% | $1.74B | |
-39.58% | $599.50M | |
-20.15% | $2.27B | |
-47.66% | $5.84B | |
-35.42% | $983.90M | |
32.93% | $89.59M | |
-68.93% | $277.29M | |
-22.40% | $1.49B | |
-51.77% | $45.33M | |
251.33% | $1.29B | |
-143.74% | $17.21M | |
-28.37% | $922.99M | |
-225.62% | $37.41M | |
-46.60% | $1.40B | |
73.27% | $435.60M | |
313.56% | $137.42M | |
100.06% | $3.62B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aldeyra Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aldeyra Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aldeyra Therapeutics, Inc.'s ROE?
How is the ROE calculated for Aldeyra Therapeutics, Inc. (ALDX)?
What is the highest ROE for Aldeyra Therapeutics, Inc. (ALDX)?
What is the 3-year average ROE for Aldeyra Therapeutics, Inc. (ALDX)?
What is the 5-year average ROE for Aldeyra Therapeutics, Inc. (ALDX)?
How does the current ROE for Aldeyra Therapeutics, Inc. (ALDX) compare to its historical average?